MétaCan
Menu
Back to cohort
Record W4387745881 · doi:10.1136/bmjment-2023-300771

Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs

2023· review· en· W4387745881 on OpenAlexaff
Guillaume Fond, Jasmina Mallet, Mathieu Urbach, Michael E. Benros, Michael Berk, Martina Billeci, Laurent Boyer, Christoph U. Correll, Michele Fornaro, Jayashri Kulkarni, Marion Leboyer, Pierre‐Michel Llorca, D. Misdrahi, Romain Rey, Franck Schürhoff, Marco Solmi, Iris E. Sommer, Stephen M. Stahl, Baptiste Pignon, Fabrice Berna

Bibliographic record

VenueBMJ Mental Health · 2023
Typereview
Languageen
FieldMedicine
TopicSchizophrenia research and treatment
Canadian institutionsOttawa HospitalUniversity of Ottawa
FundersNational Health and Medical Research Council
KeywordsMedicineSchizophrenia (object-oriented programming)Adjunctive treatmentPharmacologyBioinformaticsHormonePsychiatryIntensive care medicineInternal medicineBiology

Abstract

fetched live from OpenAlex

QUESTION: This umbrella review and guidelines aimed to provide evidence to support the rational choice of selected adjunctive therapies for schizophrenia. STUDY SELECTION AND ANALYSIS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and World Federation of Societies of Biological Psychiatry (WFSBP)-grading recommendations, 63 randomised control trials (RCTs) (of which 4219 unique participants have completed the RCTs) and 29 meta-analyses were analysed. FINDINGS: Provisional recommendations (WFSBP-grade 1) could be made for two molecules in augmentation to antipsychotics: (1) N-acetyl-cysteine (NAC, 1200-3600 mg/day, for >12 consecutive weeks) in improving negative symptoms, general psychopathology (positive and negative syndrome scale for schizophrenia (PANSS) general psychopathology factor (G)-G subscale), with the RCTs with the longer duration showing the most robust findings; (2) polyunsaturated fatty acids (3000 mg/day of eicosapentaenoic acid, for >12 weeks) in improving general psychopathology. Weaker recommendations (ie, WFSBP-grade 2) could be drawn for sarcosine (2 g/day) and minocycline (200-300 mg/day) for improving negative symptoms in chronic schizophrenia (not early schizophrenia), and NAC for improving positive symptoms and cognition. Weak recommendations are not ready for clinical practice. There is provisional evidence that oestrogens and raloxifene are effective in some patients, but further research is needed to determine their benefit/risk ratio. CONCLUSIONS: The results of this umbrella review should be interpreted with caution as the number of RCTs included in the meta-analyses was generally small and the effect sizes were weak or medium. For NAC, two RCTs with low risk of bias have provided conflicting results and the WFSBP-grade recommendation included also the results of meta-analyses. These drugs could be provisionally prescribed for patients for whom no other treatments have been effective, but they should be discontinued if they prove ineffective.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.087
metaresearch head score (Gemma)0.169
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.087
Threshold uncertainty score0.462

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0870.169
Meta-epidemiology (narrow)0.0030.002
Meta-epidemiology (broad)0.0130.014
Bibliometrics0.0120.010
Science and technology studies0.0020.003
Scholarly communication0.0080.010
Open science0.0080.005
Research integrity0.0090.006
Insufficient payload (model declined to judge)0.0110.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.127
GPT teacher head0.457
Teacher spread0.330 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations27
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueBMJ Mental HealthSame topicSchizophrenia research and treatmentFrench-language works237,207